Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost? New research shows that Lecanemab and Donanemab can delay cognitive decline and expand the independence of patients in daily activities.…
Dementia Australia welcomes UK approval of lecanemab to tackle Alzheimer’s Dementia Australia welcomes the Medicines and Healthcare Products Regulatory Agency’s decision to approve Lecanemab for use in the UK. Lecanemab…
Lecanemab effectively targets amyloid plaques in people with Down syndrome, study finds People with Down syndrome are likely to develop Alzheimer’s disease at a young age. Autopsy studies show that by age…
